{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:54:32Z","timestamp":1770479672077,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,15]],"date-time":"2008-01-15T00:00:00Z","timestamp":1200355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abst ract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pyoderma gangrenosum (PG) is a rare neutrophilic, ulcerating dermatosis that is frequently difficult to diagnose and often a diagnosis of exclusion. It is hypothesized that PG may be caused by an abnormal T\u2010cell and neutrophil response, which correlates with its common link to other disorders, such as inflammatory bowel disease, rheumatoid arthritis, and malignancies. Several treatments have been used successfully for PG, but none has proven to be universally effective.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We present three cases of PG treated with adalimumab after failed courses of steroids (orally and parenterally), thalidomide, cyclosporine, and mycophenolate mofetil.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Patients 2 and 3, who had previously responded to infliximab, albeit with recurrence, were successfully treated with adalimumab at a dose of 40\u00a0mg once a week. Patient 1 initially responded to adalimumab, but after 7.5\u00a0months failed to show wound bed improvement at a dose of 80\u00a0mg\/week subcutaneously. This patient had not previously been treated with infliximab.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> We believe adalimumab to be a valuable alternative for the treatment of PG, with comparable efficacy to infliximab.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2008.03412.x","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T12:00:11Z","timestamp":1253188811000},"page":"192-194","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pyoderma gangrenosum \u2013 rebel without a cure?"],"prefix":"10.1111","volume":"47","author":[{"given":"Sharon E.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn S.","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410031909"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.12.1427"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.172"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/75.8.842"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079897"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000042245.20042.4f"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082004000600008"},{"key":"e_1_2_5_9_2","first-page":"441","article-title":"Treatment of pyoderma gangrenosum with etanercept","volume":"3","author":"McGowan JW","year":"2004","journal-title":"J Drugs Dermatol Aug"},{"key":"e_1_2_5_10_2","first-page":"196","article-title":"Adalimumab: human recombinant immunoglobulin G1 anti\u2010tumor necrosis factor monoclonal antibody","volume":"4","author":"Baker DE","year":"2004","journal-title":"Rev Gastroenterol Disorder"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740410005467"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06582.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410017284"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1157\/13077774"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2008.03412.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2008.03412.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:16:01Z","timestamp":1696875361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2008.03412.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,15]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-4632.2008.03412.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03412.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,15]]},"assertion":[{"value":"2008-01-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}